Endocrine therapy, often an aromatase inhibitor (AI), in combination with a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor is the recommended first-line treatment option for certain patients with HR-positive/HER2-negative advanced breast cancer both internationally [5–7] and in Japan [8]. This evidence concerns the gene CYP19A1 and breast cancer.